内臓リーシュマニア症の世界市場レポート 2025年

内臓リーシュマニア症市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.8%で、13億3,000万米ドルに成長する見込みです。予測期間中に予想される成長は、ワクチン開発への投資の増加、世界の疾病監視プログラムの強化、官民パートナーシップの高まり、顧みられない熱帯病への資金提供の拡大、遺伝子ベースの治療法の進歩などに起因しています。この期間に予想される主な動向には、CRISPRベースの遺伝子編集、AI主導の創薬、ナノテクノロジーによるドラッグデリバリー、寄生虫分析のための次世代シーケンサー、早期発見のためのウェアラブルバイオセンサー、医療サプライチェーン管理のためのブロックチェーン技術、スマートフォンベースの診断ツール、個別化治療研究のための3Dバイオプリンティングなどがあります。

栄養失調の有病率の増加は、今後数年間の内臓リーシュマニア症市場の拡大を促進すると予想されます。栄養不良とは、最適な身体機能に必要な必須栄養素の摂取不足または不均衡によって引き起こされる健康状態を指します。この増加は、栄養価の高い食品へのアクセスを制限し、栄養不足と免疫系を低下させる微量栄養素の欠乏をもたらす食料不安によるところが大きいです。免疫力が低下すると、内臓リーシュマニア症のような感染症にかかりやすくなります。栄養不足は身体の病原体に対する防御能力を低下させ、重篤な病気や関連する合併症を引き起こす可能性を高める。例えば、2024年7月、イタリアに本部を置く国連関連機関である食糧農業機関は、栄養不足の人の数が2021年の7億870万人から2022年には7億2,380万人に増加したと報告しました。その結果、栄養不良の発生率の増加が内臓リーシュマニア症市場の成長に拍車をかけています。

内臓リーシュマニア症市場の主なプレーヤーは、特にこの病気が流行している地域において、治療効果を高め患者へのアクセスを拡大するために、改良された抗寄生虫薬などの先進的な治療オプションの開発を優先しています。抗寄生虫薬は、寄生虫の重要なプロセスを阻害することにより、寄生虫の宿主内での成長、繁殖、生存を阻害し、寄生虫感染症を治療するように設計されています。例えば、2024年2月、インドの製薬会社Zydus Lifesciences Limitedは、カラアザールとしても知られるリーシュマニア症の治療薬として、ミルテフォシンの原薬（API）と製剤の両方について世界保健機関（WHO）の事前承認を取得しました。ミルテフォシンは経口抗寄生虫薬で、寄生虫の細胞膜と代謝プロセスを破壊し、最終的に死滅させる。このため、内臓リーシュマニア症.

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界内臓リーシュマニア症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の内臓リーシュマニア症市場：成長率分析
• 世界の内臓リーシュマニア症市場の実績：規模と成長, 2019-2024
• 世界の内臓リーシュマニア症市場の予測：規模と成長, 2024-2029, 2034F
• 世界内臓リーシュマニア症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の内臓リーシュマニア症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 駆虫薬
• 抗真菌剤
• その他の治療法
• 世界の内臓リーシュマニア症市場診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清学的検査
• 分子検査
• 顕微鏡検査
• 培養方法
• 世界の内臓リーシュマニア症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• その他の投与経路
• 世界の内臓リーシュマニア症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の内臓リーシュマニア症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の内臓リーシュマニア症市場、抗寄生虫薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 五価アンチモン
• ミルテホシン
• パロモマイシン
• シタマクイン
• 併用療法
• 世界の内臓リーシュマニア症市場抗真菌剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンホテリシンB
• リポソームアムホテリシンB（アムビソーム）
• アゾール
• エキノキャンディン
• ポリエン
• 世界の内臓リーシュマニア症市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• モノクローナル抗体
• ワクチンベースのアプローチ
• 光線力学療法
• 遺伝子治療

第7章 地域別・国別分析

• 世界の内臓リーシュマニア症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の内臓リーシュマニア症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 内臓リーシュマニア症市場：競合情勢
• 内臓リーシュマニア症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
• Aurobindo Pharma Limited
• Cipla Limited
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Limited
• Alkem Laboratories Ltd
• Xellia Pharmaceuticals
• Knight Therapeutics Inc
• Gufic Biosciences Ltd.
• United Biotech Private Limited
• DNDi
• TLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 内臓リーシュマニア症市場2029：新たな機会を提供する国
• 内臓リーシュマニア症市場2029：新たな機会を提供するセグメント
• 内臓リーシュマニア症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Visceral leishmaniasis, also known as kala-azar, is a serious parasitic disease caused by Leishmania species and transmitted through the bite of an infected sandfly. It primarily affects internal organs such as the liver, spleen, and bone marrow, leading to symptoms such as persistent fever, weight loss, anemia, and organ enlargement. If left untreated, the disease can be fatal, highlighting the importance of early detection and prompt treatment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary treatment options for visceral leishmaniasis include antiparasitic, antifungal, and other types of therapies. Antiparasitic treatments consist of drugs or interventions that specifically target and eliminate parasites by interfering with their biological functions, thereby inhibiting their growth, reproduction, or survival. Diagnosis involves a range of methods, including serological tests, molecular techniques, microscopy, and culture-based approaches. Treatments are administered via various routes, including oral, injectable, and other alternative delivery methods. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by different end users such as hospitals, home care settings, specialty clinics, and other healthcare facilities.

The visceral leishmaniasis market research report is one of a series of new reports from The Business Research Company that provides visceral leishmaniasis market statistics, including visceral leishmaniasis industry global market size, regional shares, competitors with a visceral leishmaniasis market share, detailed visceral leishmaniasis market segments, market trends and opportunities, and any further data you may need to thrive in the visceral leishmaniasis industry. This visceral leishmaniasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The visceral leishmaniasis market size has grown strongly in recent years. It will grow from$1.00 billion in 2024 to $1.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be credited to several factors, including a rising disease burden, increased government funding, the introduction of amphotericin B, the development of miltefosine, expanded awareness campaigns, enhanced healthcare access in endemic areas, and the formation of public-private partnerships.

The visceral leishmaniasis market size is expected to see strong growth in the next few years. It will grow to$1.33 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth in the forecast period can be attributed to increased investment in vaccine development, strengthened global disease surveillance programs, rising public-private partnerships, greater funding for neglected tropical diseases, and advancements in gene-based therapies. Key trends expected during this period include CRISPR-based gene editing, AI-driven drug discovery, nanotechnology-enhanced drug delivery, next-generation sequencing for parasite analysis, wearable biosensors for early detection, blockchain technology for medical supply chain management, smartphone-based diagnostic tools, and 3D bioprinting for personalized treatment research.

The growing prevalence of malnutrition is expected to drive the expansion of the visceral leishmaniasis market in the coming years. Malnutrition refers to a health condition caused by insufficient or imbalanced intake of essential nutrients needed for optimal body function. This rise is largely attributed to food insecurity, which restricts access to nutritious food, resulting in undernourishment and micronutrient deficiencies that compromise the immune system. A weakened immune system increases the body's vulnerability to infections such as visceral leishmaniasis. Nutritional deficiencies reduce the body's ability to defend against pathogens, thereby raising the likelihood of severe disease and related complications. For instance, in July 2024, the Food and Agriculture Organization, a UN-affiliated agency based in Italy, reported that the number of undernourished individuals increased to 723.8 million in 2022, up from 708.7 million in 2021. As a result, the increasing incidence of malnutrition is fueling the growth of the visceral leishmaniasis market.

Key players in the visceral leishmaniasis market are prioritizing the development of advanced treatment options, such as improved antiparasitic medications, to enhance therapeutic efficacy and broaden patient access, especially in regions where the disease is endemic. Antiparasitic drugs are designed to treat parasitic infections by interfering with the parasite's vital processes, thereby inhibiting its growth, reproduction, or survival inside the host. For example, in February 2024, Zydus Lifesciences Limited, an Indian pharmaceutical firm, secured World Health Organization (WHO) prequalification for both the active pharmaceutical ingredient (API) and formulation of miltefosine for treating leishmaniasis, also known as kala-azar. Miltefosine is an oral antiparasitic that disrupts the parasite's cell membrane and metabolic processes, ultimately leading to its death. This makes it a highly effective oral option for treating visceral leishmaniasis.

In January 2023, Gilead Sciences Inc., a U.S.-based biopharmaceutical company specializing in visceral leishmaniasis treatments, renewed its collaboration with the World Health Organization (WHO) to expand access to therapies for this condition. As part of the partnership, Gilead Sciences is donating 304,700 vials of AmBisome (liposomal amphotericin B) to increase the availability of essential medicines for treating visceral leishmaniasis in countries with a high disease burden. This initiative supports global efforts to combat and eliminate the disease. The WHO, a specialized agency headquartered in Switzerland, plays a critical role in the prevention, control, and eradication of visceral leishmaniasis through coordinated health programs and strategic global initiatives.

Major players in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, and TLC.

North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in visceral leishmaniasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the visceral leishmaniasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The visceral leishmaniasis market consists of revenues earned by entities by providing services such as drug development and distribution, vector control programs, and research and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The visceral leishmaniasis market also includes sales of antileishmanial drugs, vaccines, vector control insecticides, recombinant antigen-based diagnostics, and polymerase chain reaction (PCR)-based detection kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Visceral Leishmaniasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on visceral leishmaniasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for visceral leishmaniasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The visceral leishmaniasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Antiparasitic; Antifungal; Other Treatments
• 2) By Diagnosis Method: Serological Tests; Molecular Tests; Microscopy; Culture Methods
• 3) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Antiparasitic: Pentavalent Antimonials; Miltefosine; Paromomycin; Sitamaquine; Combination Therapy
• 2) By Antifungal: Amphotericin B; Liposomal Amphotericin B (AmBisome); Azoles; Echinocandins; Polyenes
• 3) By Other Treatments: Immunotherapy; Monoclonal Antibodies; Vaccine-Based Approaches; Photodynamic Therapy; Gene Therapy
• Companies Mentioned: Pfizer Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; Novartis AG; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Visceral Leishmaniasis Market Characteristics

3. Visceral Leishmaniasis Market Trends And Strategies

4. Visceral Leishmaniasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Visceral Leishmaniasis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Visceral Leishmaniasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Visceral Leishmaniasis Market Growth Rate Analysis
• 5.4. Global Visceral Leishmaniasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Visceral Leishmaniasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Visceral Leishmaniasis Total Addressable Market (TAM)

6. Visceral Leishmaniasis Market Segmentation

• 6.1. Global Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiparasitic
• Antifungal
• Other Treatments
• 6.2. Global Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serological Tests
• Molecular Tests
• Microscopy
• Culture Methods
• 6.3. Global Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes Of Administration
• 6.4. Global Visceral Leishmaniasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Visceral Leishmaniasis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Antiparasitic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pentavalent Antimonials
• Miltefosine
• Paromomycin
• Sitamaquine
• Combination Therapy
• 6.7. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Antifungal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amphotericin B
• Liposomal Amphotericin B (AmBisome)
• Azoles
• Echinocandins
• Polyenes
• 6.8. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Monoclonal Antibodies
• Vaccine-Based Approaches
• Photodynamic Therapy
• Gene Therapy

7. Visceral Leishmaniasis Market Regional And Country Analysis

• 7.1. Global Visceral Leishmaniasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Visceral Leishmaniasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Visceral Leishmaniasis Market

• 8.1. Asia-Pacific Visceral Leishmaniasis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Visceral Leishmaniasis Market

• 9.1. China Visceral Leishmaniasis Market Overview
• 9.2. China Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Visceral Leishmaniasis Market

• 10.1. India Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Visceral Leishmaniasis Market

• 11.1. Japan Visceral Leishmaniasis Market Overview
• 11.2. Japan Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Visceral Leishmaniasis Market

• 12.1. Australia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Visceral Leishmaniasis Market

• 13.1. Indonesia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Visceral Leishmaniasis Market

• 14.1. South Korea Visceral Leishmaniasis Market Overview
• 14.2. South Korea Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Visceral Leishmaniasis Market

• 15.1. Western Europe Visceral Leishmaniasis Market Overview
• 15.2. Western Europe Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Visceral Leishmaniasis Market

• 16.1. UK Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Visceral Leishmaniasis Market

• 17.1. Germany Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Visceral Leishmaniasis Market

• 18.1. France Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Visceral Leishmaniasis Market

• 19.1. Italy Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Visceral Leishmaniasis Market

• 20.1. Spain Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Visceral Leishmaniasis Market

• 21.1. Eastern Europe Visceral Leishmaniasis Market Overview
• 21.2. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Visceral Leishmaniasis Market

• 22.1. Russia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Visceral Leishmaniasis Market

• 23.1. North America Visceral Leishmaniasis Market Overview
• 23.2. North America Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Visceral Leishmaniasis Market

• 24.1. USA Visceral Leishmaniasis Market Overview
• 24.2. USA Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Visceral Leishmaniasis Market

• 25.1. Canada Visceral Leishmaniasis Market Overview
• 25.2. Canada Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Visceral Leishmaniasis Market

• 26.1. South America Visceral Leishmaniasis Market Overview
• 26.2. South America Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Visceral Leishmaniasis Market

• 27.1. Brazil Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Visceral Leishmaniasis Market

• 28.1. Middle East Visceral Leishmaniasis Market Overview
• 28.2. Middle East Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Visceral Leishmaniasis Market

• 29.1. Africa Visceral Leishmaniasis Market Overview
• 29.2. Africa Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Visceral Leishmaniasis Market Competitive Landscape And Company Profiles

• 30.1. Visceral Leishmaniasis Market Competitive Landscape
• 30.2. Visceral Leishmaniasis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Visceral Leishmaniasis Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Gilead Sciences Inc.
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Dr. Reddy's Laboratories
• 31.5. Aurobindo Pharma Limited
• 31.6. Cipla Limited
• 31.7. Zydus Lifesciences Limited
• 31.8. Glenmark Pharmaceuticals Limited
• 31.9. Alkem Laboratories Ltd
• 31.10. Xellia Pharmaceuticals
• 31.11. Knight Therapeutics Inc
• 31.12. Gufic Biosciences Ltd.
• 31.13. United Biotech Private Limited
• 31.14. DNDi
• 31.15. TLC

32. Global Visceral Leishmaniasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Visceral Leishmaniasis Market

34. Recent Developments In The Visceral Leishmaniasis Market

35. Visceral Leishmaniasis Market High Potential Countries, Segments and Strategies

• 35.1 Visceral Leishmaniasis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Visceral Leishmaniasis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Visceral Leishmaniasis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35025_Visceral_Leishmaniasis_GMR_2025